The amount of LNFPII extracted and separated from natural breast milk is relatively little, and the separation processes are time-consuming and expensive. Therefore, creating these molecules by artificial synthesis could be the best bet. CD BioGlyco offers different kinds of analytical reagents for LNFPII.

Production Methods of LNFPII

Fucosylated oligosaccharides have critical physiological functions in immune response, signal transduction, early embryogenesis and development, growth control, apoptosis, pathogen adherence, and other processes. Human milk oligosaccharides (HMOs), including fucosylated oligosaccharides, now be synthesized by chemical, enzymatic, and cell factory processes.

A sialyl-Lewis, called LNFPII, is a human Lewis blood-group determinant. LNFPII is currently produced primarily through Chemical and Enzymatic synthesis; trace amounts can be obtained through purification; cell factory production techniques are currently in the development and experimental stages and, with luck, will be used in the future for large-scale LNFPII production.

Fig.1 The structure of LNFPII. (Guzmán-Rodríguez, et al., 2018)

LNFPII Production Service at CD BioGlyco

CD BioGlyco provides a powerful synthesis platform that could provide the high-quality synthesis services of LNFPII. According to the client's requirements, we provide different scales and grades of products for clients. Moreover, because LNFPII is an important compound of HMOs, which is a precursor for a number of medical markers, CD BioGlyco provides the Analytical Platform for HMOs. It is a great tool to help clients study the potential application of LNFPII.

For example, CA 19-9, a monosilane-ganglioside/glycolipid and sialyl derivative of LNFPII, is a key marker for biliopancreatic cancer. In biliopancreatic malignancies, particularly pancreatic cancer, CA 19-9 correlates well with the clinical course of the disease after surgical, chemo-, or radiotherapy by a rapid return to normalcy within 2-4 weeks after complete surgery, a brief decline with successful palliative therapy, and an often-anticipated increase in case of relapse or progressive disease.

Advantages of Us

• We have an advanced synthesis and analysis platform for LNFPII to provide customized services.
• We have the ability to provide different scales and grades of LNFPII to meet clients' needs.
• We have great scientists and an outstanding service team for helping with clients' research.
• We have great experience and achievements in the field of HMO research.

CD BioGlyco would like to be your helper in scientific research and provide you with high-quality LNFPII products. If you are interested in the production service for LNFPII, please feel free to contact us for more detailed information. We look forward to receiving inquiries from all over the world and will do our best to help you.

Reference:

1. Guzmán-Rodríguez, F.; et al. Employment of fucosidases for the synthesis of fucosylated oligosaccharides with biological potential. Biotechnology and Applied Biochemistry. 2018, 66(2): 172–191.